Experienced in Schizophrenia

Dr. Rishi Kakar

Psychiatry
7481 W Oakland Park Blvd, Ste 100, 
Tamarac, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Schizophrenia
7481 W Oakland Park Blvd, Ste 100, 
Tamarac, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rishi Kakar is a Psychiatrist in Tamarac, Florida. Dr. Kakar is rated as an Experienced provider by MediFind in the treatment of Schizophrenia. His top areas of expertise are Schizophrenia, Schizoaffective Disorder, Major Depression, and Bipolar Disorder (BPD). Dr. Kakar is currently accepting new patients.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 4 clinical trials in the study of Schizophrenia.

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

7481 W Oakland Park Blvd, Ste 100, Tamarac, FL 33319
Other Locations
11440 N Kendall Dr, Ste 208, Miami, FL 33176
1601 N Palm Ave, Ste 211, Pembroke Pines, FL 33026
1065 NE 125th St, Ste 206, North Miami, FL 33161
10301 Hagen Ranch Rd, Ste B6, Boynton Beach, FL 33437

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Enrollment Status: Recruiting
Publish Date: July 28, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
Enrollment Status: Completed
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drug: BTRX-335140
Study Phase: Phase 2
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
Enrollment Status: Terminated
Publish Date: December 20, 2024
A Double-blind, Oral, Multiple-dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
A Double-blind, Oral, Multiple-dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Enrollment Status: Completed
Publish Date: September 23, 2024
Intervention Type: Drug
Study Drug: Endoxifen
Study Phase: Phase 3
A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDD
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDD
Enrollment Status: Completed
Publish Date: November 01, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Study to Evaluate the PK Profiles of LY03010 and Relative Bioavailability at Steady-state of LY03010 Versus INVEGA SUSTENNA in Schizophrenia Patients
A Study to Evaluate the PK Profiles of LY03010 and Relative Bioavailability at Steady-state of LY03010 Versus INVEGA SUSTENNA in Schizophrenia Patients
Enrollment Status: Completed
Publish Date: April 25, 2023
Intervention Type: Drug
Study Drugs: LY03010, Sustenna
Study Phase: Phase 1
A Single Arm, Adaptive Design, Pivotal Trial to Assess the Efficacy of AKL-T01, a Novel Digital Intervention Designed to Improve Attention, in Adults Diagnosed With Attention Deficit Hyperactive Disorder
A Single Arm, Adaptive Design, Pivotal Trial to Assess the Efficacy of AKL-T01, a Novel Digital Intervention Designed to Improve Attention, in Adults Diagnosed With Attention Deficit Hyperactive Disorder
Enrollment Status: Completed
Publish Date: February 28, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Enriched-Enrollment Withdrawal, Multicenter Study to Evaluate the Efficacy and Safety of a Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Subjects With Moderate to Severe Chronic Low Back Pain Currently Treated With Daily Opioids
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Enriched-Enrollment Withdrawal, Multicenter Study to Evaluate the Efficacy and Safety of a Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Subjects With Moderate to Severe Chronic Low Back Pain Currently Treated With Daily Opioids
Enrollment Status: Completed
Publish Date: October 15, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
Enrollment Status: Terminated
Publish Date: September 05, 2021
Intervention Type: Combination product
Study Drug: ABILIFY MYCITE
Study Phase: Phase 3
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: July 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Enrollment Status: Completed
Publish Date: July 09, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
Enrollment Status: Completed
Publish Date: January 30, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Controlled, 6-week Trial to Assess the Impact of Novel Digital Interventions Designed to Improve Cognitive Dysfunction as Adjunct Therapy to Antidepressant Medication in Adults With Major Depressive Disorder
A Randomized, Double-blind, Controlled, 6-week Trial to Assess the Impact of Novel Digital Interventions Designed to Improve Cognitive Dysfunction as Adjunct Therapy to Antidepressant Medication in Adults With Major Depressive Disorder
Enrollment Status: Completed
Publish Date: November 21, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 13 Less Clinical Trials

11 Total Publications

A Phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder.
A Phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder.
Journal: Current medical research and opinion
Published: October 16, 2025
Similar Doctors
Distinguished in Schizophrenia
Dr. Patrick Pinchinat
Psychiatry | Addiction Medicine
Distinguished in Schizophrenia
Dr. Patrick Pinchinat
Psychiatry | Addiction Medicine
18503 Pines Blvd, Suite 215, 
Pembroke Pines, FL 
 (14.2 miles away)
954-392-6099
Languages Spoken:
English, French, Haitian, Haitian Creole
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Pinchinat is a Psychiatrist and an Addiction Medicine provider in Pembroke Pines, Florida. Dr. Pinchinat is rated as a Distinguished provider by MediFind in the treatment of Schizophrenia. His top areas of expertise are Schizophrenia, Schizoaffective Disorder, Major Depression, and Bipolar Disorder (BPD). Dr. Pinchinat is currently accepting new patients.

Distinguished in Schizophrenia
Dr. Nelson E. Cordero-Torres
Psychiatry | Child and Adolescent Psychiatry
Distinguished in Schizophrenia
Dr. Nelson E. Cordero-Torres
Psychiatry | Child and Adolescent Psychiatry

Ventre Medical Associates LLC

7369 Sheridan St, Suite 101, 
Hollywood, FL 
 (9.4 miles away)
954-561-6222
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Nelson Cordero-Torres is a Psychiatrist and a Child and Adolescent Psychiatrist in Hollywood, Florida. Dr. Cordero-Torres is rated as an Advanced provider by MediFind in the treatment of Schizophrenia. His top areas of expertise are Bipolar Disorder (BPD), Schizophrenia, Schizoaffective Disorder, and Major Depression. Dr. Cordero-Torres is currently accepting new patients.

Distinguished in Schizophrenia
Dr. Rhaisa A. Dumenigo
Psychiatry
Distinguished in Schizophrenia
Dr. Rhaisa A. Dumenigo
Psychiatry
78 Sw 13th Ave, Suite 201, 
Miami, FL 
 (27.3 miles away)
305-644-5600
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Rhaisa Dumenigo is a Psychiatrist in Miami, Florida. Dr. Dumenigo is rated as a Distinguished provider by MediFind in the treatment of Schizophrenia. Her top areas of expertise are Schizophrenia, Bipolar Disorder (BPD), Major Depression, and Seasonal Affective Disorder (SAD). Dr. Dumenigo is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kakar's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile